Enhancement of plasminogen binding to U937 cells and fibrin by complestatin

Thrombosis and Haemostasis

Volumn 77, Issue 1, 1997, Pages 137-142

  Tachikawa, Kiyoshi ^a   Hasumi, Keiji ^a   Endo, Akira ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; COMPLESTATIN; FIBRIN; IODINE 125; LIPOPROTEIN A; PLASMIN; PLASMINOGEN;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; HUMAN CELL; ISOTOPE LABELING; MONOCYTE; PRIORITY JOURNAL; PROTEIN BINDING;

EID: 0031042402     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1655921     Document Type: Article

References (40)

1. Robbins KC, Summaria L, Hsieh B, Shah RJ. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 1967; 242: 2333-42.
2. Váli Z, Patthy L. Location of the intermediate and high affinity ω-amino-carboxylic acid-binding sites in human plasminogen. J Biol Chem 1982; 257: 2104-10.
3. Hajjar KA, Harpel PC, Jaffe EA, Nachman RL. Binding of plasminogen to cultured human endothelial cells. J Biol Chem 1986; 261: 11656-62.
4. Miles LA, Plow EF. Plasminogen receptors: ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 1988; 2: 61-71.
5. Blasi F. Surface receptors for urokinase plasminogen activator. Fibrinolysis 1988; 2: 73-84.
6. Miles LA, Plow EF. Binding and activation of plasminogen on the platelet surface. J Biol Chem 1985; 260: 4303-11.
7. Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986; 103: 2411-20.
8. Stephens RW, Pöllänen J, Tapiovaara H, Leung K-C, Sim P-S, Salonen E-M, Rønne E, Behrendt N, Danø K, Vaheri A. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol 1989; 108: 1987-95.
9. 2-antiplasmin and leupeptin. Biochem J 1991; 275: 53-9.
10. 2-macroglobulin. J Biol Chem 1991; 266: 12329-36.
11. Berg K. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand 1963; 59: 369-82.
12. McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132-7.
13. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339: 301-3.
14. Hajjar KA, Gavish D, Breslow JL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339: 303-5.
15. Gonzalez-Gronow M, Edelberg JM, Pizzo SV. Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein(a) competes for the same site. Biochemistry 1989; 28: 2374-7.
16. Kluft C, Jie AFH, Los P, de Wit E, Havekes L. Functional analogy between lipoprotein(a) and plasminogen in the binding to the kringle 4 binding protein, tetranectin. Biochem Biophys Res Commun 1989; 161: 427-33.
17. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10: 240-5.
18. Rouy D, Koschinsky ML, Fleury V, Chapman J, Anglés-Cano E. Apolipoprotein(a) and plasminogen interact with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments. Biochemistry 1992; 31: 6333-9.
19. Ezratty A, Simon DI, Loscalzo J. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry 1993; 32: 4628-33.
20. Seto H, Fujioka T, Furihata K, Kaneko I, Takahashi S. Structure of complestatin, a very strong inhibitor of protease activity of complement in the human complement system. Tetrahedron Lett 1989; 30: 4987-90.
21. Kaneko I, Kamoshida K, Takahashi S. Complestatin, a potent anti-complement substance produced by Streptomyces lavendulae. I. Fermentation, isolation and biological characterization. J Antibiot (Tokyo) 1989; 42: 236-41.
22. Momota K, Kaneko I, Kimura S, Mitamura K, Shimada K. Inhibition of human immunodeficiency virus type-1-induced syncytium formation and cytopathicity by complestatin. Biochem Biophys Res Commun 1991; 179: 243-50.
23. Goldstein JL, Basu SK, Brown MS. Receptor-mediated endocytosis of low density lipoprotein in cultured cells. Methods Enzymol 1983; 98: 241-60.
24. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
25. Hartert H, Schaeder JA. The physical and biological constants of thrombelastography. Biorheology 1962; 1: 31-9.
26. Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw Jr RW, Starzl TE, Winter PM. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985; 64: 888-96.
27. Thorsen S. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids. Biochim Biophys Acta 1975; 393: 55-65.
28. Thorsen S, Clemmensen I, Sottrup-Jensen L, Magnusson S. Adsorption to fibrin of native fragments of known primary structure from human plasminogen. Biochim Biophys Acta 1981; 668: 377-87.
29. Van Zonneveld A-J, Veerman H, Pannekoek H. On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by ε-amino caproic acid. J Biol Chem 1986, 261: 14214-8.
30. Ichinose A, Takio K, Fujikawa K. Localization of the binding site of tissue-type plasminogen activator to fibrin. J Clin Invest 1986; 78: 163-9.
31. Kaneko I, Fearon DT, Austein KF. Inhibition of the alternative pathway of human complement in vitro by a natural product, complestatin. J Immunol 1980; 124: 1194-8.
32. Pollanen J. Down-regulation of plasmin receptors on human sarcoma cells by glucocorticoids. J Biol Chem 1989; 264: 5628-32.
33. Félez J, Miles LA, Plescia J, Plow EF. Regulation of plasminogen receptor expression on human monocytes and monocytoid cell lines. J Cell Biol 1990; 111: 1673-83.
34. 3 and their combination. Thromb Res 1993; 69: 353-9.
35. Kim BS, Plow EF, Miles LA. Regulation of plasminogen receptor expression on monocytoid THP-1 cells by adherence to extracellular matrix proteins. Circulation 1992; 86: I-148a (Abstract).
36. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J 1995, 9: 939-45.
37. Camacho M, Fondanèche M-C, Burtin P. Limited proteolysis of tumor cells increases their plasmin-binding activity. FEBS Lett 1989; 245: 21-4.
38. Gonzalez-Gronow M, Stack S, Pizzo SV. Plasmin binding to the plasminogen receptor enhances catalytic efficiency and activates the receptor for subsequent ligand binding. Arch Biochem Biophys 1991; 286: 625-8.
39. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as candidate plasminogen receptor. Biochemistry 1991; 30: 1682-91.
40. Scott J. Thrombogenesis linked to atherogenesis at last? Nature 1989; 341: 22-3.